発熱性好中球減少症の世界市場レポート 2025年

発熱性好中球減少症市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.4％で、144億8,000万米ドルに成長します。予測期間中の成長は、免疫抑制剤の使用拡大、研究開発（R&D）の増加、有利な償還政策、投資の増加、白血病患者の増加などの要因によるものと考えられます。この期間の主な動向には、迅速な分子診断、抗菌薬スチュワードシップと脱スケーリング療法の採用、免疫療法と標的治療、リスク層別化モデルの開発、真菌バイオマーカーの進歩などがあります。

がんの有病率の増加が、今後数年間の発熱性好中球減少症市場の成長を牽引すると予想されます。がんは、近くの組織に侵入して全身に広がる可能性のある異常細胞の制御不能な増殖によって特徴づけられる複雑な一連の疾患です。がんの罹患率の上昇は、高齢化、環境および職業上の曝露、遺伝的素因、ホルモンおよび生殖因子などの要因によるところが大きいです。発熱性好中球減少症は、化学療法中の感染リスクの上昇を強調し、早期介入を促し、生命を脅かす合併症を予防するための標的治療を可能にすることで、がん患者をサポートする上で重要な役割を果たしています。これにより、患者の転帰を改善し、がん治療を適時に継続することができます。例えば、2022年1月、米国がん協会は、米国では新たに190万人のがん患者と60万9,360人のがん関連死が予想され、毎日1,670人近くが死亡していると報告しました。したがって、がんの有病率の増加が発熱性好中球減少症市場の成長を促進しています。

発熱性好中球減少症市場の主なプレーヤーは、治療へのアクセス性を高めるため、先進的なバイオシミラー医薬品の開発に注力しています。バイオシミラー医薬品は、構造、機能、効能において、承認された参照医薬品を忠実に反映した生物製剤です。バイオシミラー医薬品はオリジナルの生物製剤に代わる費用対効果の高い代替品を提供し、厳しい規制基準を遵守しながら患者アクセスを向上させる。例えば、ドイツに本社を置く製薬会社フレゼニウス・カビは2022年9月、バイオシミラーであるStimufend（pegfilgrastim-fpgk）について米国食品医薬品局（FDA）の承認を取得しました。この承認により、骨髄抑制的化学療法を受けている非骨髄性悪性腫瘍の患者において、白血球数の低下と発熱を特徴とする発熱性好中球減少症を引き起こす可能性のあるStimufendの使用が可能となりました。同社は、プレフィルドシリンジタイプのStimufendを2023年初頭に発売する予定であり、将来の使用に向けて体内注射器も開発中です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界発熱性好中球減少症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の発熱性好中球減少症市場：成長率分析
• 世界の発熱性好中球減少症市場の実績：規模と成長, 2019-2024
• 世界の発熱性好中球減少症市場の予測：規模と成長, 2024-2029, 2034F
• 世界発熱性好中球減少症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の発熱性好中球減少症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経験的抗生物質療法
• 標的抗生物質療法
• 支持療法
• 世界の発熱性好中球減少症市場リスク要因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法誘発性好中球減少症
• 移植関連好中球減少症
• 遺伝性疾患
• 世界の発熱性好中球減少症市場病因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グラム陰性細菌
• グラム陽性細菌
• 真菌感染症
• ウイルス感染
• 世界の発熱性好中球減少症市場：診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液培養
• 画像検査
• 骨髄穿刺
• 世界の発熱性好中球減少症市場経験的抗生物質療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 広域スペクトルβ-ラクタム
• 糖ペプチド
• カルバペネム
• 世界の発熱性好中球減少症市場標的抗生物質療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗真菌療法
• 抗ウイルス療法
• グラム陽性細菌療法
• グラム陰性細菌療法
• 世界の発熱性好中球減少症市場支持療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 顆粒球コロニー刺激因子（G-CSF）
• 静脈内輸液
• 解熱剤と疼痛管理

第7章 地域別・国別分析

• 世界の発熱性好中球減少症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の発熱性好中球減少症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 発熱性好中球減少症市場：競合情勢
• 発熱性好中球減少症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Fresenius Kabi
• Aurobindo Pharma Ltd.
• Lupin Limited
• Mundipharma GmbH
• BeyondSpring Inc.
• Hospira Inc.
• Biocon Biologics Limited
• Kyowa Kirin Co. Ltd.
• Coherus BioSciences Inc.
• Assertio Holdings Inc.
• Napp Pharmaceuticals Limited
• Gennova Biopharmaceuticals Limited
• Acrotech Biopharma Inc.
• Taiho Pharmaceutical Co. Ltd.
• Evive Biotech

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 発熱性好中球減少症市場2029：新たな機会を提供する国
• 発熱性好中球減少症市場2029：新たな機会を提供するセグメント
• 発熱性好中球減少症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Febrile neutropenia is a medical condition characterized by a fever (a temperature of 100.4°F or higher) and a low count of neutrophils, which are essential white blood cells needed to fight infections. This condition is commonly seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more susceptible to infections.

The main treatment approaches for febrile neutropenia include empirical antibiotic therapy, targeted antibiotic therapy, and supportive care. Empirical antibiotic therapy involves initiating treatment with broad-spectrum antibiotics based on clinical assessment before identifying the exact causative pathogen. The condition is associated with various risk factors, such as chemotherapy-induced neutropenia, transplant-related neutropenia, and genetic disorders, with several potential etiologies including gram-negative bacteria, gram-positive bacteria, fungal infections, and viral infections. Diagnosis is made using various methods, such as blood cultures, imaging tests, and bone marrow aspiration.

The febrile neutropenia market research report is one of a series of new reports from The Business Research Company that provides febrile neutropenia market statistics, including the febrile neutropenia industry global market size, regional shares, competitors with the febrile neutropenia market share, detailed febrile neutropenia market segments, market trends, and opportunities, and any further data you may need to thrive in the febrile neutropenia industry. This febrile neutropenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The febrile neutropenia market size has grown strongly in recent years. It will grow from $10.60 billion in 2024 to $11.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to factors such as the rising incidence of cancer, the growing adoption of chemotherapy, the expansion of personalized medicine, efforts to reduce healthcare costs, and the increasing prevalence of neutropenia.

The febrile neutropenia market size is expected to see strong growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the growing use of immunosuppressive drugs, increasing research and development (R&D), favorable reimbursement policies, rising investments, and the increasing incidence of leukemia cases. Key trends during this period include rapid molecular diagnostics, the adoption of antimicrobial stewardship and de-escalation therapy, immunotherapy and targeted treatments, the development of risk stratification models, and advancements in fungal biomarkers.

The growing prevalence of cancer is expected to drive the growth of the febrile neutropenia market in the coming years. Cancer is a complex set of diseases marked by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread throughout the body. The rising incidence of cancer is largely due to factors such as an aging population, environmental and occupational exposures, genetic predisposition, and hormonal and reproductive factors. Febrile neutropenia plays a critical role in supporting cancer patients by highlighting the increased risk of infections during chemotherapy, encouraging early intervention, and enabling targeted treatments to prevent life-threatening complications. This helps improve patient outcomes and ensures timely continuation of cancer therapies. For example, in January 2022, the American Cancer Society reported that in the U.S., an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths were expected, with nearly 1,670 deaths occurring daily. Therefore, the increasing prevalence of cancer is driving the growth of the febrile neutropenia market.

Key players in the febrile neutropenia market are focusing on the development of advanced biosimilar drugs to increase treatment accessibility. Biosimilar drugs are biologics that closely mirror approved reference drugs in structure, function, and efficacy. They provide cost-effective alternatives to original biologics, improving patient access while complying with stringent regulatory standards. For instance, in September 2022, Fresenius Kabi, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for its biosimilar Stimufend (pegfilgrastim-fpgk). This approval allows Stimufend to be used in patients with non-myeloid malignancies who are undergoing myelosuppressive chemotherapy, which can lead to febrile neutropenia, a condition characterized by a low white blood cell count and fever. The company plans to launch Stimufend in a prefilled syringe format in early 2023 and is also developing an on-body injector for future use.

In July 2023, Assertio Holdings Inc., a U.S.-based pharmaceutical company, acquired Spectrum Pharmaceuticals for an undisclosed amount. This acquisition is aimed at expanding and diversifying Assertio's revenue base, enhancing its oncology portfolio with ROLVEDON (eflapegrastim-xnst) injection, and strengthening its commercial and digital marketing capabilities. Spectrum Pharmaceuticals is a U.S.-based company specializing in the manufacture of febrile neutropenia drugs.

Major players in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech.

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the febrile neutropenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The febrile neutropenia market consists of revenues earned by entities by providing services such as diagnostic services, hematologic support, hospitalization and monitoring, and outpatient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The febrile neutropenia market also includes sales of antibiotics, antifungal and antiviral medications, urinalysis, and urine culture. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Febrile Neutropenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on febrile neutropenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for febrile neutropenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The febrile neutropenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Empirical Antibiotic Therapy; Targeted Antibiotic Therapy; Supportive Care
• 2) By Risk Factors: Chemotherapy-Induced Neutropenia; Transplant-Related Neutropenia; Genetic Disorders
• 3) By Etiology: Gram-Negative Bacteria; Gram-Positive Bacteria; Fungal Infections; Viral Infections
• 4) By Diagnostic Methods: Blood Cultures; Imaging Tests; Bone Marrow Aspiration
• Subsegments:
• 1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams; Glycopeptides; Carbapenems
• 2) By Targeted Antibiotic Therapy: Antifungal Therapy; Antiviral Therapy; Gram-Positive Bacterial Therapy; Gram-Negative Bacterial Therapy
• 3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs); Intravenous Fluids; Antipyretics And Pain Management
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Febrile Neutropenia Market Characteristics

3. Febrile Neutropenia Market Trends And Strategies

4. Febrile Neutropenia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Febrile Neutropenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Febrile Neutropenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Febrile Neutropenia Market Growth Rate Analysis
• 5.4. Global Febrile Neutropenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Febrile Neutropenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Febrile Neutropenia Total Addressable Market (TAM)

6. Febrile Neutropenia Market Segmentation

• 6.1. Global Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Empirical Antibiotic Therapy
• Targeted Antibiotic Therapy
• Supportive Care
• 6.2. Global Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy-Induced Neutropenia
• Transplant-Related Neutropenia
• Genetic Disorders
• 6.3. Global Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gram-Negative Bacteria
• Gram-Positive Bacteria
• Fungal Infections
• Viral Infections
• 6.4. Global Febrile Neutropenia Market, Segmentation By Diagnostic Methods, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Cultures
• Imaging Tests
• Bone Marrow Aspiration
• 6.5. Global Febrile Neutropenia Market, Sub-Segmentation Of Empirical Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Beta-Lactams
• Glycopeptides
• Carbapenems
• 6.6. Global Febrile Neutropenia Market, Sub-Segmentation Of Targeted Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifungal Therapy
• Antiviral Therapy
• Gram-Positive Bacterial Therapy
• Gram-Negative Bacterial Therapy
• 6.7. Global Febrile Neutropenia Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulocyte Colony-Stimulating Factors (G-CSFs)
• Intravenous Fluids
• Antipyretics And Pain Management

7. Febrile Neutropenia Market Regional And Country Analysis

• 7.1. Global Febrile Neutropenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Febrile Neutropenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Febrile Neutropenia Market

• 8.1. Asia-Pacific Febrile Neutropenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Febrile Neutropenia Market

• 9.1. China Febrile Neutropenia Market Overview
• 9.2. China Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Febrile Neutropenia Market

• 10.1. India Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Febrile Neutropenia Market

• 11.1. Japan Febrile Neutropenia Market Overview
• 11.2. Japan Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Febrile Neutropenia Market

• 12.1. Australia Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Febrile Neutropenia Market

• 13.1. Indonesia Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Febrile Neutropenia Market

• 14.1. South Korea Febrile Neutropenia Market Overview
• 14.2. South Korea Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Febrile Neutropenia Market

• 15.1. Western Europe Febrile Neutropenia Market Overview
• 15.2. Western Europe Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Febrile Neutropenia Market

• 16.1. UK Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Febrile Neutropenia Market

• 17.1. Germany Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Febrile Neutropenia Market

• 18.1. France Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Febrile Neutropenia Market

• 19.1. Italy Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Febrile Neutropenia Market

• 20.1. Spain Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Febrile Neutropenia Market

• 21.1. Eastern Europe Febrile Neutropenia Market Overview
• 21.2. Eastern Europe Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Febrile Neutropenia Market

• 22.1. Russia Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Febrile Neutropenia Market

• 23.1. North America Febrile Neutropenia Market Overview
• 23.2. North America Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Febrile Neutropenia Market

• 24.1. USA Febrile Neutropenia Market Overview
• 24.2. USA Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Febrile Neutropenia Market

• 25.1. Canada Febrile Neutropenia Market Overview
• 25.2. Canada Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Febrile Neutropenia Market

• 26.1. South America Febrile Neutropenia Market Overview
• 26.2. South America Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Febrile Neutropenia Market

• 27.1. Brazil Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Febrile Neutropenia Market

• 28.1. Middle East Febrile Neutropenia Market Overview
• 28.2. Middle East Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Febrile Neutropenia Market

• 29.1. Africa Febrile Neutropenia Market Overview
• 29.2. Africa Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Febrile Neutropenia Market Competitive Landscape And Company Profiles

• 30.1. Febrile Neutropenia Market Competitive Landscape
• 30.2. Febrile Neutropenia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sandoz Overview, Products and Services, Strategy and Financial Analysis

31. Febrile Neutropenia Market Other Major And Innovative Companies

• 31.1. Fresenius Kabi
• 31.2. Aurobindo Pharma Ltd.
• 31.3. Lupin Limited
• 31.4. Mundipharma GmbH
• 31.5. BeyondSpring Inc.
• 31.6. Hospira Inc.
• 31.7. Biocon Biologics Limited
• 31.8. Kyowa Kirin Co. Ltd.
• 31.9. Coherus BioSciences Inc.
• 31.10. Assertio Holdings Inc.
• 31.11. Napp Pharmaceuticals Limited
• 31.12. Gennova Biopharmaceuticals Limited
• 31.13. Acrotech Biopharma Inc.
• 31.14. Taiho Pharmaceutical Co. Ltd.
• 31.15. Evive Biotech

32. Global Febrile Neutropenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Febrile Neutropenia Market

34. Recent Developments In The Febrile Neutropenia Market

35. Febrile Neutropenia Market High Potential Countries, Segments and Strategies

• 35.1 Febrile Neutropenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Febrile Neutropenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Febrile Neutropenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer